Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform

The success of chimeric antigen receptor (CAR) T-cell therapy against hematologic malignancies has altered the treatment paradigm for patients with these diseases. Nevertheless, the occurrence of relapse due to antigen escape or heterogeneous antigen expression on tumors remains a challenge for firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Borrok, M. Jack, Li, Yonghai, Harvilla, Paul B., Vellalore Maruthachalam, Bharathikumar, Tamot, Ninkka, Prokopowitz, Christine, Chen, Jun, Venkataramani, Sathya, Grewal, Iqbal S., Ganesan, Rajkumar, Singh, Sanjaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980914/
https://www.ncbi.nlm.nih.gov/pubmed/36874404
http://dx.doi.org/10.1158/2767-9764.CRC-21-0150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980914/
https://www.ncbi.nlm.nih.gov/pubmed/36874404
http://dx.doi.org/10.1158/2767-9764.CRC-21-0150

Ejemplares similares